BMS-345541: Difference between revisions

Revision as of 20:29, 28 March 2023 editIsla (talk \| contribs)Extended confirmed users2,449 edits never marketed← Previous edit		Latest revision as of 19:52, 20 December 2023 edit undoJJMC89 bot III (talk \| contribs)Bots, Administrators3,754,596 editsm Moving Category:Merck brands to Category:Drugs developed by Merck per Misplaced Pages:Categories for discussion/Log/2023 December 9#Category:AstraZeneca brands
Line 59:		Line 59:

	]		]
	]		]

Latest revision as of 19:52, 20 December 2023

Chemical compound Pharmaceutical compound

BMS-345541
Identifiers

IUPAC name 4-(2′-Aminoethyl)amino-1,8-dimethylimidazoquinoxaline
CAS Number	445430-58-0
PubChem CID	9813758
IUPHAR/BPS	5669
ChemSpider	7989508
UNII	26SU0NEF5F
ChEMBL	ChEMBL249697
CompTox Dashboard (EPA)	DTXSID60196216
Chemical and physical data
Formula	C₁₄H₁₇N₅
Molar mass	255.325 g·mol
3D model (JSmol)	Interactive image
SMILES n1c3c(n2c(cnc2c1NCCN)C)cc(cc3)C
InChI InChI=1S/C14H17N5/c1-9-3-4-11-12(7-9)19-10(2)8-17-14(19)13(18-11)16-6-5-15/h3-4,7-8H,5-6,15H2,1-2H3,(H,16,18) Key:PSPFQEBFYXJZEV-UHFFFAOYSA-N
(what is this?) (verify)

BMS-345541, developed by Merck KGaA, is an anti-inflammatory, cell-permeable quinoxaline compound. It is an allosteric site-binding inhibitor with a primary target of IKK-2 and blocks the NF-κB-dependent transcription in mice.

It has no approvals for human/medical use or for use in clinical trials. No clinical trials mention it.